heart failure – Medxy AI

Comparing Cardiac MRI and Coronary Angiography for Diagnosing Ischemic Cardiomyopathy in New-Onset Heart Failure

By MedXY 09/22/2025

A multicenter trial shows cardiac MRI offers comparable sensitivity to invasive coronary angiography for diagnosing ischemic cardiomyopathy, reducing invasive procedures in newly diagnosed heart failure patients.

Clinical Updates Wellness & Lifestyle

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

By MedXY 09/20/2025

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.

Clinical Updates Wellness & Lifestyle

Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact

By MedXY 09/16/2025

A prespecified subanalysis of the PACMAN-HF trial demonstrates that individualized nutritional interventions in chronic heart failure patients at risk of malnutrition improve nutritional status and functional capacity but do not significantly affect mortality or heart failure hospitalizations.

Clinical Updates Wellness & Lifestyle

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.

Clinical Updates Wellness & Lifestyle

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY 09/08/2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Clinical Updates Wellness & Lifestyle

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

By MedXY 09/07/2025

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF in hospitalized patients.

Clinical Updates Wellness & Lifestyle

Fontan Circulatory Failure and Heart Transplant Survival: Insights from a Multicenter Retrospective Cohort Study

By MedXY 09/06/2025

This study identifies key Fontan circulatory failure morbidities impacting survival from heart transplant waitlisting through one year post-transplant, highlighting cyanosis and frequent hospitalizations as critical risk factors.

Clinical Updates Wellness & Lifestyle

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

By MedXY 09/06/2025

The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.

Clinical Updates Wellness & Lifestyle

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

By MedXY 09/03/2025

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

Clinical Updates Wellness & Lifestyle

Myocardial T1 Mapping and Extracellular Volume: Emerging Prognostic Tools in Heart Failure and Non-Ischaemic Dilated Cardiomyopathy

By MedXY 09/03/2025

Cardiac MRI T1 mapping and extracellular volume fraction (ECV) provide noninvasive markers of myocardial fibrosis, showing consistent prognostic value across heart failure subtypes and non-ischaemic dilated cardiomyopathy for adverse cardiovascular outcomes.

Clinical Updates Wellness & Lifestyle

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

By MedXY 09/02/2025

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer adverse events.

Clinical Updates Wellness & Lifestyle

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

By MedXY 09/02/2025

Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.

Clinical Updates Wellness & Lifestyle

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

By MedXY 09/02/2025

This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and therapeutic target discovery.

Clinical Updates Wellness & Lifestyle

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

By MedXY 09/02/2025

Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.

Clinical Updates Wellness & Lifestyle

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY 08/31/2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Clinical Updates Wellness & Lifestyle

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

By MedXY 08/30/2025

The DIGIT-HF trial sheds new light on digitoxin's role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Clinical Updates Wellness & Lifestyle

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

By MedXY 08/30/2025

The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glycoside under strict dosing protocols.

Wellness & Lifestyle

Heart Failure Isn’t Scary — Ignoring Early Signs Is: Prevention for 6 High-Risk Groups

By MedXY 08/27/2025

Heart failure is a serious but manageable condition. Recognizing early symptoms and understanding risk factors can save lives. Here’s a comprehensive guide on prevention, diagnosis, and management for both the public and health professionals.

Clinical Updates Wellness & Lifestyle

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

By MedXY 08/19/2025

Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.

Clinical Updates Wellness & Lifestyle

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

By MedXY 08/17/2025

A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.